Pyridine amides as potent and selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

Several series of pyridine amides were identified as selective and potent 11beta-HSD1 inhibitors. The most potent inhibitors feature 2,6- or 3,5-disubstitution on the pyridine core. Various linkers (CH(2)SO(2), CH(2)S, CH(2)O, S, O, N, bond) between the distal aryl and central pyridyl groups are tolerated, and lipophilic amide groups are generally favored. On the distal aryl group, a number of substitutions are well tolerated. A crystal structure was obtained for a complex between 11beta-HSD1 and the most potent inhibitor in this series.

[1]  Jyoti R. Patel,et al.  Synthesis and structural activity relationship of 11beta-HSD1 inhibitors with novel adamantane replacements. , 2006, Bioorganic & medicinal chemistry letters.

[2]  C. Pavlides,et al.  11β-Hydroxysteroid dehydrogenase functions reversibly as an oxidoreductase in the rat hippocampus in vivo , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  R. Dilley,et al.  Light and Electron Microscopy Localization of the 11β-Hydroxysteroid Dehydrogenase Type I Enzyme in the Rat. , 2001, Endocrinology.

[4]  A. Jeng,et al.  Perhydroquinolylbenzamides as novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. , 2005, Journal of medicinal chemistry.

[5]  L. Abrahmsén,et al.  Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. , 2002, Journal of medicinal chemistry.

[6]  C. Edwards,et al.  Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. , 1999, The Journal of clinical investigation.

[7]  R. Thieringer,et al.  Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. , 2005, Bioorganic & medicinal chemistry letters.

[8]  Jeremy W Tomlinson,et al.  11 (cid:1) -Hydroxysteroid Dehydrogenase Type 1: A Tissue-Specific Regulator of Glucocorticoid Response , 2004 .

[9]  L. Abrahmsén,et al.  Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. , 2003, Endocrinology.

[10]  J. Flier,et al.  A Transgenic Model of Visceral Obesity and the Metabolic Syndrome , 2001, Science.

[11]  J. Flier,et al.  Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. , 2003, The Journal of clinical investigation.

[12]  K. Longenecker,et al.  Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors , 2007 .

[13]  P. Stewart,et al.  Does central obesity reflect “Cushing's disease of the omentum”? , 1997, The Lancet.

[14]  R. Kluge,et al.  Sulfonic peracids — III. Heteroatom oxidation and chemoselectivity , 1996 .

[15]  A J Howie,et al.  Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. , 1998, The Journal of clinical endocrinology and metabolism.

[16]  K. Longenecker,et al.  Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation. , 2007, Bioorganic & medicinal chemistry letters.

[17]  R. Thieringer,et al.  Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome. , 2005, Bioorganic & medicinal chemistry letters.

[18]  J. McKew,et al.  β-Keto sulfones as inhibitors of 11β-hydroxysteroid dehydrogenase type I and the mechanism of action , 2007 .

[19]  Edwards,et al.  11 b-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress , 1997 .

[20]  R. Henry,et al.  Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors. , 2007, Journal of medicinal chemistry.

[21]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[22]  A. Howie,et al.  Detection of human 11β-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts , 1995, Molecular and Cellular Endocrinology.

[23]  B. Walker,et al.  Effects of the 11β-Hydroxysteroid Dehydrogenase Inhibitor Carbenoxolone on Insulin Sensitivity in Men with Type 2 Diabetes , 2003 .

[24]  Thierry Langer,et al.  The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening. , 2006, Journal of medicinal chemistry.

[25]  John J. Mullins,et al.  Improved Lipid and Lipoprotein Profile, Hepatic Insulin Sensitivity, and Glucose Tolerance in 11β-Hydroxysteroid Dehydrogenase Type 1 Null Mice* , 2001, The Journal of Biological Chemistry.

[26]  C. Edwards,et al.  11 beta-hydroxysteroid dehydrogenase bioactivity and messenger RNA expression in rat forebrain: localization in hypothalamus, hippocampus, and cortex. , 1990, Endocrinology.